Discussion on Section H
|
|
- Lynn Carpenter
- 5 years ago
- Views:
Transcription
1 Discussion on Section H Risks of Estrogen Therapy (Part 2) Cancer Chairman: lv!r R. B. K. Rickford Mr R. B. K. Rickford (Chairman): Professor Sellwood gave estrogens to his male rats and they developed carcinoma. Did he ever think of giving them estrogens and progestogens. I also hoped that he might explain to me, as a mere gynaecologist, why we are sometimes asked to take ovaries out of patients with carcinoma of the breast, and why some patients with carcinoma of the breast are given massive doses of estrogens. Professor R. A. Sellwood (Surgeon, Manchester): I shall take the second question first. We have the concept of estrogen-dependence. Someone coined the term a long time ago, to explain the dramatic remission of the disease that occurs in about 30~ ~ of pre-menopausal women following removal of the ovaries. I cannot explain why in post-menopausal women, or at least in women who are 5 or 6 years beyond the menopause, an equally dramatic remission can be obtained by giving estrogens. Perhaps we are wrong to talk about estrogen dependence. Perhaps we should simply say that anything we do which drastically alters the sex hormone environment alters the responsiveness of the tumour. The estrogens that we give are synthetic and generally speaking they are either stilbestrol or ethinyl estradiol. One could postulate that their effect is to block the receptors on the tumour cells on which the endogenous estrogens normally work and produce their effect, but I have no evidence that this IS so. The work on rats was not mine. It is American work and I do not think that anyone has studied the effects of estrogen and progestogen together in the male rat. Mr E. S. Saunders (Gynaecologist, London): Professor Dewhurst has been kind enough to mention my work. My statistics published in 1960 concerned 500 cases which were treated with hormone implants. The duration was 15 years, and not 5 years. The expected number of cancers, according to the general population, would have been about 30; there were no cancers in my treated patients. 351
2 352 THE MANAGEMENT OF THE MENOPAUSE Professor Dewhurst referred to another group where two cases of cancer of the uterus were found. Those two cases are very interesting, from every point of view. One case came to see me because of severe flushes and palpitations, and also osteoporosis. I gave her the usual implant. Ten days later that woman came back complain- ing of bleeding. A thorough examination was done, and a curettage showed a polyp which was examined by the pathologist who reported malignant changes on the tip of the polyp. We cannot claim than an implant done IO days earlier provoked a cancer of the endometrium. The second case of cancer was also interesting. The patient was aged about 49 or 50, with a history of irregular periods, a slight loss every few weeks, and because of her severe menopausal symptoms-she showed no signs of malignancy-i gave her an implant. Three weeks later she came with bleeding. A curettage showed carcinoma of the endometrium. From the point of view of statistics, I have to put those cases in, although I am convinced that they have nothing to do with the implant. A second statistic of mine has not been mentioned. The material was presented at a Congress in Vienna. There were 600 cases, selected menopausal women, about the same age group. They were divided into two groups. Three hundred were given a placebo but the other three hundred were treated with implants. Ten years later a follow up of most of the cases showed that the women who had received implants had 2t times less cancer than the others. To conclude: Professor Dewhurst has said that there is no evidence that estrogen might not produce a cancer, but there is no evidence either that estrogen has produced cancers. Mr S. Campbell (Gynaecologist, London): In our 6-month crossover placebo trial which we described earlier, the patients had an outpatient (Vabra) curettage on admission to the study and again after 6 months Premarin and 6 months placebo. Twentysix of the 39 patients who had intact uteri had withdrawal bleeding on Premarin 1 25 mg, an incidence of 67 0 which is very much higher than the Io-20~~ which is quoted in the literature. A total of 6 patients (9 o) had cystic glandular hyperplasia while on Premarin 1 25 mg but did not have it on placebo. That is a very high incidence and although I quite accept that this may not be a pre-cancerous lesion, it worries me considerably. We have had one case of cancer of the endometrium in a patient who before she came to our clinic, had been one year on continuous Premarin. We put her on a cyclical dosage but discovered cancer of the endometrium a few months later when we performed Vabra curettage. The conclusion I would draw is that we cannot be complacent about the risks of cancer of the endometrium. We must use the minimum dosage to control symptoms, and for any patient with regular withdrawal bleeding I would recommend a 6- monthly Vabra curettage or preferably the. addition of a progestogen to the therapy. More and more I am using a regime of continuous estrogen, and for the first week of every calendar month prescribing norethisterone, 5 mg daily. Since adopting this regime we have had no cases of hyper stimulation of the endometrium and I feel very much happier when I see that situation. Professor C. J. Dewhurst (Gynaecologist, London): I share Mr Campbell's concern
3 SECTION H: RISKS OF ESTROGEN THERAPY 353 about cystic glandular hyperplasia. The fact that millions of women on the Pill which contains estrogen and progestogen, do not develop cancer, is irrelevant as to whether estrogens alone do. That is one of my points. I do not think that these facts are clearly stated in many of the papers, and my purpose here is to suggest that we should still look, and go on looking critically at the evidence that estrogens alone over long periods of time are free from risk. Ms. Tove Wisborg (Copenhagen): In the past 10 years we have seen five cases of estrogen-produced ovarian cancer and one case of breast cancer. We thought that there llught be a connection with a contmuous high level of estrogen in the body, compared with normal cyclic variations. Perhaps it might be advisable not to use continuous estrogen in post-menopausal women, but to use intermittent therapy. Professor R. A. Sellwood: I would be most interested in the data. The information is new to me. Professor C. J. Dewhurst: For other reasons, I would always approve intermittent therapy, but that is hardly relevant to the question. Mr E. V. van Hall (Lei den) : Did Professor selwood do the same studies in postmenopausal breast cancer patients? They are the more interesting group. Also it would be interesting to look at estrone, and perhaps androgens. Professor R. A. Sellwood: We have done this in post-menopausal women. We have got a group of about 30 or 40 post-menopausal women with cancer of the breast, and 30 or 40 normal women. The estradiol I7-{1 is so low in the post-menopausal women that it is at the lower limit of sensitivity of our assay, and I can make no comment about it. We have not yet measured the prolactin in those women. It should be more interesting. Of course Mr Van Hall is right. What we really want to measure is estrone, but as yet we cannot produce an antibody. Professor C. Lauritzen (Gynaecologist, Ulm): I have some comments on estrogens and mammary carcinoma. We have discussed estrogens, carcinoma of the breast, and of the endometrium, but we would be very short-sighted, or even blind, to look only at estrogens. I cannot let the discussion go without mentioning that genetic factors in the human are of great importance in mammary carcinoma, and the risk factor if a mother has a carcinoma of the breast, for the daughter, is about 5, and for disturbances of the cycle, such as anovulation, it is 2. This is a great difference*t. Professor R. A. Sellwood: It is even greater when a sister has cancer of the breast. Professor C. Lauritzen (Ulm): There is also growing evidence that mammary carcinoma may also be virus-induced.:!: I refer to the study of McMahon and co-workers*, which has not been mentioned. The risk for mammary carcinoma increases fourfold if the first pregnancy is later than 25 years. The prolactin levels are much higher at night than by day, so prolactin levels * MacMahon and Cole (1969). Callcer, 24, 1146 t Zippin and Petrallis (1971). Callcer, 28, 1381 :j: Moore et al. (1971). Nature (Lolldoll), I
4 354 THE MANAGEMENT OF THE MENOPAUSE should be studied at night*. If Professor Sellwood has some plasma left, he should use it to determine androgens too. Mr R. B. K. Rickford (Chairman): Could an American surgeon give his views on the length of time that post-menopausal women should take estrogens? To the grave? To 80, to 70, or how long? Dr C. B. Hammond (Gynaecologist, Duke University): It is nice to be asked an easy question! I plan to touch on this tomorrow in my paper and I can only give my own personal opinion. I think that there is a group of patients in whom estrogen therapy, or hormonal therapy, is beneficial. It should be carried Out for the treatment of the symptoms that they have. I am not a' member of the school which advocates estrogen for all women for all time, and I should like to leave it at that until I can lfesent the data. Dr P. Bye (Schering Chemicals, Sussex): On the question of mammary carcinoma, it may be germane to quote from, a publication that has just come out-a WHO monograph on carcinogenic risks of various types of drugs. The latest volume deals with the sex hormones. They reviewed all the data on long-term studies, those that Professor Dewhurst mentioned, and others. They made the same methodological criticisms that he made, but they came to the conclusion that despite the methodological shortcomings, they could go so far as to say that whereas it had not been proved that the risk of mammary carcinoma was reduced by the use of estrogens, at least it could be said that there was no indication of any increased risk. Dr N. G. Mussalli (Gynaecologist, Welwyn Garden City): Professor Sellwood has described clinical investigations and hormone assays in patients with breast cancer, with cystic disease of the breast and in normal controls. Extensive work has been done, especially by veterinary colleagues, on the physiology of the breast in relation to lactation. This involved tissue cultures using hormones. Could the responsiveness of the target organ be helpful in investigating this disease? Professor R. A. Sellwood: The questioner I believe suggests that if we set up cultures of mammary tumours against a battery of either hormonal or cytotoxic agents, rather in the same way that we set up cultures of a bacterium against antibiotics, we might find a sensitivity, so to speak. We might be able to pick out the tumour that will respond to estrogen, and the one that will respond to androgen. Quite a lot of tissue culture work has been done' and I have done some myself. Overall I would say that the results are very disappointing. This is because it is so very difficult to culture cancer of the breast. Almost every other cancer can be cultured by fairly straightforward methods but cancer of the breast is so often nearly all fibrous tissue and very few tumour cells. All of us who have worked in the field have had the most terrible difficulty in getting reliable standard cultures of the type that would be needed to do this. One or two peopl~ claim to have done so, and there have been suggestions that it might be possible, but I cannot go further than that. Dr Muriel G. Yates (General Practitioner, Liverpool): Could Premarin be given to a patient with severe menopausal symptoms who has had a radical mastectomy? Professor R. A. Sellwood: I know of no reason why not except for a patient with * Nokin et al. (1972). Br. Med.].,
5 SECTION H: RISKS OF ESTROGEN THERAPY 355 advanced cancer of the breast who was being treated by bilateral oophorectomy. That would imply that she was a pre-menopausal woman, and most unlikely to be undergoing menopausal symptoms. If the symptoms were produced by doing the oophorectomy, I would not then give the hormone; having done the operation to remove estrogens, and I would not put them back. Miss G. S. Agerbak (Copenhagen): On the basis of the data we have heard today, does the panel consider it possibly advantageous to advocate a sequential therapy, that is estrogen plus progestogen at the end of the cycle for post-menopausal women? Professor C. J. Dewhurst: The problem would be one of patient acceptability. I should have thought that many patients would not want to go on menstruating, which by and large they would do for a period of time. However, from the point of view of cancer risk, combined estrogen/progestogen therapy would be preferable to estrogens alone. I believe that it would be preferable to use a progestogen occasionally, two or three times a year: to strip the endometrium effectively, so that probably the hyperplasia about which I am concerned would not then occur. Mr S. Campbell: Professor Dewhurst is absolutely right. Post-menopausal women do not like to have regular periods, but on the other hand, if they are given a choice between suffering menopausal symptoms or having regular withdrawal bleeding, they opt for regular withdrawal bleeding any day; they are very willing to accept this small inconvenience. Mr R. B. K. Rickford: To sum up. Estrogens are possibly dangerous, depending perhaps on dosage, and also perhaps on the length of time that they are given to post-menopausal women. There may be a lot to be said for giving a progestogen with them.
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationMy Father Has a Mood. Disorder
My Father Has a Mood Disorder 1996 Bipolar Support Canterbury Inc. Reprinted 2004 Illustrations by Judy Lee Bipolar Support Canterbury would like to acknowledge the assistance of J R McKenzie Trust and
More information--- or not, and do we need to come up with newer strategies for ovarian cancer screening.
My name is Dr. Karen Lu and I am a Professor of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. I also serve as Co-Medical Director for Clinical Cancer Genetics. I m going to
More informationBreast Cancer How to reduce your risk
Prevention Series Breast Cancer How to reduce your risk Let's Make Cancer History 1 888 939-3333 www.cancer.ca Breast Cancer How to reduce your risk Breast cancer develops in abnormal cells in the breast
More informationWomen s Health Initiative (WHI) Study How July 2002 changed menopausal management and what the study really says. Robert P.
3400-A Old Milton Pkwy Ste 360 Alpharetta GA 30005 770.475.0077 georgiahormones.com Women s Health Initiative (WHI) Study How July 2002 changed menopausal management and what the study really says. Robert
More informationPalm Beach Obstetrics & Gynecology, PA
Palm Beach Obstetrics & Gynecology, PA 4671 S. Congress Avenue, Lake Worth, FL 33461 561.434.0111 4631 N. Congress Avenue, Suite 102, West Palm Beach, FL 33407 Endometriosis The lining of the uterus is
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationAcceptability and Clinical Effectivity of the Oral Progestogens for Fertility Control in Indian Women
Acceptability and Clinical Effectivity of the Oral Progestogens for Fertility Control in Indian Women PRABHAKER N. SHAH, M.D., F.C.P.S. EVEN IN ADVANCED countries today, the practice of family planning
More information4:00 into mp3 file Huang_342831_5_v1.mp3
Support for Yale Cancer Answers comes from AstraZeneca, providing important treatment options for women living with advanced ovarian cancer. Learn more at astrazeneca-us.com. Welcome to Yale Cancer Answers
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationbleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the
Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis
More informationUnraveling Recent Cervical Cancer Screening Updates and the Impact on Your Practice
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationHormone Treatments and the Risk of Breast Cancer
Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State (BCERF) Updated July 2002 Hormone Treatments and the Risk of Breast Cancer 1) Hormone Treatment After Menopause
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes
More informationSo, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
More informationPRESS RELEASE. NICE issues first guideline on menopause to stop women suffering in silence
EMBARGOED UNTIL: 00.01hrs, THURSDAY 12 NOVEMBER 2015 PRESS RELEASE NICE issues first guideline on menopause to stop women suffering in silence More than a million women could benefit from the first NICE
More informationDifference between vagifem and yuvafem
Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone
More informationTHE IMPACT OF OUR PRESS, MEDIA AND INFORMATION AND ADVICE
1 THE IMPACT OF OUR PRESS, MEDIA AND INFORMATION AND ADVICE 2 CONTENTS Stand Alone s website Information and Advice Focus on Christmas - December 2015 Other press work in 2015 The overall impact of our
More informationWhat Are Genes And Chromosomes?
Clinical Genetics Predictive testing for a Breast Cancer 2(BRCA2) Gene alteration Information for families where an altered cancer gene has been found and who are considering undergoing predictive testing
More informationX-Plain Ovarian Cancer Reference Summary
X-Plain Ovarian Cancer Reference Summary Introduction Ovarian cancer is fairly rare. Ovarian cancer usually occurs in women who are over 50 years old and it may sometimes be hereditary. This reference
More informationSiteman Cancer Center Locations
Siteman Cancer Center Locations Washington University Medical Campus 4921 Parkview Place St. Louis, MO 63110 St. Charles County 150 Entrance Way St. Peters, MO 63376 West St. Louis County 10 Barnes West
More informationSection 4 Decision-making
Decision-making : Decision-making Summary Conversations about treatments Participants were asked to describe the conversation that they had with the clinician about treatment at diagnosis. The most common
More informationWORTH A CLOSER LOOK.
A birth control pill... WORTH A CLOSER LOOK. Ask your healthcare provider about. Please see Important Safety Information including Boxed Warning throughout this brochure and on pages 4 and 5. offers a
More informationCombining Individualized Treatment Options with Patient-Clinician Dialogue
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPuberty and Fertility. Normal Female Puberty PUBERTY! What about girls with Galactosemia? E Puberty and Fertility Badik Spencer 1
Puberty and Fertility Jennifer Badik*, MD Pediatric Endocrinology and Jessica Spencer*, MD, MSc Reproductive Endocrinology and Infertility Part One PUBERTY! *no conflicts of interest to report Every girl
More informationMenopause & HRT. Rosie & Alex. Image:
Menopause & HRT Rosie & Alex Image: http://www.keepcalm-o-matic.co.uk/ Menopause The permanent cessation of menstruation for 12 months When does it happen? Average age 51 Image: Nature Medicine - 12, 612-613
More informationFrom Hormone Hell to Hormone Well Straight Talk Women (and Men) Need to Know to Save Their Sanity, Health, and Quite Possibly Their Lives
For Immediate Release Contact: Kim Weiss (800) 851-9100 ext. 212 Or kimw@hcibooks.com From Hormone Hell to Hormone Well Straight Talk Women (and Men) Need to Know to Save Their Sanity, Health, and Quite
More informationMenstrual Disorders & Ambulatory Gynaecology
Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible
More informationShould women get testosterone by the NHS to boost their sex drives? Experts divide over the use of male hormones to cure sexual desire disorder
Should women get testosterone by the NHS to boost their sex drives? Experts divide over the use of male hormones to cure sexual desire disorder dailymail.co.uk/health/article-3831645/should-women-testosterone-nhs-boost-sex-drives-experts-divide-use-malehormones-cure-sexual-desire-disorder.html
More informationThis information explains the advice about familial breast cancer (breast cancer in the family) that is set out in NICE guideline CG164.
Familial breast cancer (breast cancer in the family) Information for the public Published: 1 June 2013 nice.org.uk About this information NICE guidelines provide advice on the care and support that should
More informationEndometriosis Information Leaflet
Endometriosis Information Leaflet What is Endometriosis? Endometriosis is a condition where tissue similar to the lining of the womb (endometrium) is found outside the womb. About 1 out of 10 women of
More informationOvarian Cancer Causes, Risk Factors, and Prevention
Ovarian Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for ovarian cancer.
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationPatient Education. Breast Cancer Prevention. Cancer Center
Patient Education Breast cancer affects one in nine women in the US by the time they reach their 80 s. It is the result of several mutations or alterations in the genes found in the DNA of normal breast
More informationInformation for you. Managing premenstrual syndrome (PMS) What is PMS?
Managing premenstrual syndrome (PMS) Information for you Published in August 2009 What is PMS? Premenstrual syndrome or PMS is the name given to a collection of physical and emotional symptoms that can
More informationThe Estrogen Question
The Estrogen Question Hormone Therapy still offers the best relief for menopausal symptoms. Is it right for you? When 49-year-old Lee Ann Dodson heard the news that the Women's Health Initiative (WHI)
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationTHE NUTRI-SPEC LETTER. Volume 14 Number 4. From: Guy R. Schenker, D.C. April, Dear Doctor, Is your patient suffering from:
THE NUTRI-SPEC LETTER Volume 14 Number 4 From: Guy R. Schenker, D.C. April, 2003 Dear Doctor, Is your patient suffering from: - Elevated cholesterol? - Hypertension and irregular heartbeat? - Fatigue and
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
About you Your name: xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Name of your organisation: The Prostate Cancer Charity Are you (tick all that apply): an employee of a patient organisation that represents
More informationTopics. Periods Menopause & HRT Contraception Vulva problems
Girls stuff Topics Periods Menopause & HRT Contraception Vulva problems Menorrhagia Excessive menstrual loss occurring with regular or irregular cycles Ovulatory Anovulatory Usual blood loss 30-40ml per
More informationBefore beginning this activity, be sure to review the faculty and commercial support disclosures, as well as the Learning Objectives.
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?
Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force
More informationOne of the commonest gynecological cancers,especially in white Americans.
Gynaecology Dr. Rozhan Lecture 6 CARCINOMA OF THE ENDOMETRIUM One of the commonest gynecological cancers,especially in white Americans. It is a disease of postmenopausal women with a peak incidence in
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More information5. Summary of Data Reported and Evaluation
168 IARC MONOGRAPHS VOLUME 91 5. Summary of Data Reported and Evaluation 5.1 Exposure data The first oral hormonal contraceptives that were found to inhibit both ovulation and implantation were developed
More informationHelping Cancer Patients with Quality of Life Issues Post Hysterectomy
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/helping-cancer-patients-with-quality-of-life-issuespost-hysterectomy/3548/
More informationMammography. The Lebanese Society of Obstetrics and Gynecology. Women s health promotion series
The Lebanese Society of Obstetrics and Gynecology Women s health promotion series Mammography When breast cancer is diagnosed at an early stage it could be treated and the patient would have a high chance
More informationDefeating Colon Cancer with Surgery
Defeating Colon Cancer with Surgery Recorded on: September 19, 2012 Alessandro Fichera, M.D. Director, Colorectal Surgical Oncology Program, Seattle Cancer Care Alliance Please remember the opinions expressed
More informationHepatitis C Virus (HCV): Current Screening Guidelines and Treatment Approaches
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/hepatitis-c-virus-hcvcurrent-screening-guidelines-treatment-approaches/9514/
More informationWOMENCARE A Healthy Woman is a Powerful Woman (407) Mammography
Mammography WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 Mammography is an X-ray technique used to study the breasts. It can help doctors find breast cancer at an early stage (when treatment
More informationAssessment Materials: Deb Rumsey (with Lynda Ballou) 1. "Study Suggests Light to Back of Knee Alters Biological Clock" (NY Times, 1/16/98)
Assessment Materials: Deb Rumsey (with Lynda Ballou) Out of Class Exercises 1. "Study Suggests Light to Back of Knee Alters Biological Clock" (NY Times, 1/16/98) Subjects were divided into two groups.
More informationHow HRT and the Pill Can Lead to Breast Cancer: New Research Suggests Possible Treatment
How HRT and the Pill Can Lead to Breast Cancer: New Research Suggests Possible Treatment ScienceDaily (Sep. 29, 2010) Breast cancer is one of the most common cancers, affecting up to one in eight women
More information5. Summary of Data Reported and Evaluation
288 5. Summary of Data Reported and Evaluation 5.1 Exposure Oral contraceptives have been used since the early 1960s and are now used by about 90 million women worldwide. The pill is given as a combination
More informationIVF while taking Estrace? 3,915 conversations on the web about experiences with taking Estrace before or after having a IVF.
IVF while taking Estrace? 3,915 conversations on the web about experiences with taking Estrace before or after having a IVF. Progesterone and estrogen after transfer - posted in Ask the Embryologist: Hello
More informationFrequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.
Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationTHE SAFETY CHECK LIST BEFORE STARTING HT
THE SAFETY CHECK LIST BEFORE STARTING HT This safety checklist was designed by the Endocrine Society in 2015 to minimize the chance of giving hormone therapy to women who may be negatively affected by
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationThe Following information was accessed from the book Hypothyroidism, Health & Happiness by Steven F. Hotze, MD
The Following information was accessed from the book Hypothyroidism, Health & Happiness by Steven F. Hotze, MD Autoimmune Thyroiditis After Pregnancy In women, autoimmune thyroiditis often occurs during
More informationContraception and gynecological pathologies
1 Contraception and gynecological pathologies 18 years old, 2 CMI normal First menstruation at 14 years old Irregular (every 2/3 months), painful + She does not need contraception She is worried about
More informationWORLD AIDS DAY HIV in the UK Let s End It. World AIDS Day is celebrated annually on 1st December. Produced by NAT (National AIDS Trust)
WORLD AIDS DAY 2017 HIV in the UK Let s End It World AIDS Day is celebrated annually on 1st December Produced by NAT (National AIDS Trust) Supported by Do Overview Understanding HIV: Key facts Life with
More informationTop 5 Fertility Secrets Revealed
Top 5 Fertility Secrets Revealed by Melinda Stevens Brought to you by http://www.pregnancy-online.info All rights reserved, 2007. Copyright 2007, Pregnancy-Online.info 2 Hi, thanks for downloading my free
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationI MAY NOT HAVE ALL THE ANSWERS BUT AT LEAST I HAVE THE QUESTIONS TO GET THE PROPER. care guidelines
I MAY NOT HAVE ALL THE ANSWERS BUT AT LEAST I HAVE THE QUESTIONS TO GET THE PROPER care guidelines Hi, Being diagnosed with breast cancer is tough at any age, but being diagnosed when you re young makes
More informationCASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology
CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationPrescribing advice for the management of menopause in primary care
Prescribing advice for the management of menopause in primary care This guidance contains suggested advice for the management and treatment of women experiencing symptoms of menopause. It applies to Camden
More informationOhio Northern University HealthWise. Authors: Alexis Dolin, Andrew Duska, Hannah Lamb, Eric Miller, Pharm D Candidates 2018 May 2018
Women s Health Authors: Alexis Dolin, Andrew Duska, Hannah Lamb, Eric Miller, Pharm D Candidates 2018 May 2018 Let Your Body Empower You! National Women s Health Week Polycystic Ovary Syndrome Page 2 Breast
More information5 Mousa Al-Abbadi. Ola Al-juneidi & Obada Zalat. Ahmad Al-Tarefe
5 Mousa Al-Abbadi Ola Al-juneidi & Obada Zalat Ahmad Al-Tarefe Abnormal Uterine Bleeding (AUB) AUB is a very common scenario or symptom where women complain of menorrhagia (heavy and/or for long periods),
More informationColitis Clinical Trials. Survey Results. To Start off, how would you describe yourself? (Mandatory)
Colitis Clinical Trials Survey Results 1 To Start off, how would you describe yourself? (Mandatory) 1% % % 46% 92% COUNT PERCENT i Have UC 55 92% i Know someone with UC 35 6% Other 9 2% 2 Have you ever
More informationThe Role of Adrenal Steroids in the Treatment of Tuberculosis
CLINICAL CONFERENCE The Role of Adrenal Steroids in the Treatment of Tuberculosis By Margaret H. D. Smith, M.D. Department of Pediatrics, New York University-Bellevue Medical Center DRu MARGARET H. D.
More informationDeciding whether or not to use Hormone Therapy (HT) is a big decision and should be
Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be made with input from your healthcare provider. After the decision has been made to take HT, many women don t realize
More informationDoes the hcg diet affect your period
Does the hcg diet affect your period The Borg System is 100 % Does the hcg diet affect your period 19-12-2011 hcg diet indeed provides quick weight loss, but it is also accompanied by many side effects.
More informationQuality Checking the gateway to taking control of our lives Dr THOMAS DOUKAS.
Quality Checking the gateway to taking control of our lives Dr THOMAS DOUKAS About Choice Support? Choice Support is a leading social care charity providing services to people with a wide range of support
More informationI think women coming together and speaking is really great. Hearing other women s stories was very inspiring. To hear what they have been through and
I think women coming together and speaking is really great. Hearing other women s stories was very inspiring. To hear what they have been through and come out the other side confident and strong in themselves.
More informationInformation leaflet for women with an increased lifetime risk of breast and ovarian cancer. Hereditary Breast and Ovarian Cancer (HBOC)
Information leaflet for women with an increased lifetime risk of breast and ovarian cancer Hereditary Breast and Ovarian Cancer (HBOC) What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast
More informationAsthma For Dummies PDF
Asthma For Dummies PDF The incidence of asthma is rising dramatically in the United States and across the globe. Asthma affects 17 million people in the U.S. and is the most common chronic childhood disease.
More informationManaging premenstrual syndrome (PMS)
Information for you Published in March 2018 Managing premenstrual syndrome (PMS) About this information This information is for you if you have, or think you have, premenstrual syndrome (PMS) and want
More informationWellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 2: Breast Cancer
Wellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 2: Breast Cancer Cancer Types Rev. 10.20.15 Page 19 Breast Cancer Group Discussion True False Not Sure 1. Breast cancer is not
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationFemale New Patient Package
Female New Patient Package The contents of this package are your first step to restore your vitality. Please take time to read this carefully and answer all the questions as completely as possible. Thank
More information5 MISTAKES MIGRAINEURS MAKE
5 MISTAKES MIGRAINEURS MAKE Discover the most common mistakes, traps and pitfalls that even the smart and savvy migraineurs can fall into if not forewarned. A brief & practical guide for the modern migraine
More informationContact Information. Permanent Address: Mailing Address (if different than above): Please check preferred method(s) of contact.
Contact Information Please fill out this form as completely as possible. You will not need to complete any additional medical health history forms on the day of your visit. Name: Date: Permanent Address:
More informationA cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W
A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W Record Status This is a critical abstract of an economic evaluation
More informationFemale Patient Questionnaire & History
Female Patient Questionnaire & History Name: (Last) (First) (Middle) Today s Date: Home Phone: Cell Phone: Work: E-Mail Address: Primary Care Physician s Name: May we contact you via E-Mail? ( ) YES (
More informationFemale Sexual Hormones Indications and Therapy
Female Sexual Hormones Indications and Therapy In puberty, a woman has about 400,000 ovules, at the age of 40-44 years about 17,000 only. On average, each grown-up woman (still having ovulation) loses
More informationCancer Genetics Risk Assessment Program Questionnaire
We greatly appreciate you taking the time to complete this questionnaire and look forward to meeting you. Gathering this information prior to your appointment will help make your visit with us as efficient
More informationInformation for you. Managing premenstrual syndrome (PMS) What is PMS?
Managing premenstrual syndrome (PMS) Information for you Published in August 2009 What is PMS? Premenstrual syndrome or PMS is the name given to a collection of physical and emotional symptoms that can
More informationSummary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
More informationQuestions for the Table Group
Clinical Research Study Study 1 Natalie and her daughter, Sarah I am 40 years old. I am HIV negative. My daughter s name is Sarah. She has AIDS. She is 12 years old. I have many fights with my daughter
More information58. Translarna drug Policy for use. The Hon. Member for Douglas South (Mrs Beecroft) to ask the Minister for Health and Social Care:
58. Translarna drug Policy for use The Hon. Member for Douglas South (Mrs Beecroft) to ask the Minister for Health and Social Care: What his policy is regarding the use of the drug Translarna? The President:
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationPreventive Mastectomy: Questions and Answers. Key Points. Preventive mastectomy (also called prophylactic or risk-reducing mastectomy) is the
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Preventive Mastectomy:
More informationLingo. Supported by. Insights into experiences of children and young people when talking to adults and professionals about their mental health
Lingo Supported by Insights into experiences of children and young people when talking to adults and professionals about their mental health Why Lingo? This booklet was co-produced by a Young Champion
More information